ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3046

Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome

Sean Eddy1, Viji Nair1, Hemang Parikh2, Maja Lindenmeyer3, Laura Mariani1, Felix H. Eichinger1, Huateng Huang1, Wenjun Ju2, Casey Greene4, Peter C. Grayson5, Clemens Cohen3, Jeffrey Krischer2, Peter A. Merkel6 and Matthias Kretzler1, 1Division of Nephrology, University of Michigan, Ann Arbor, MI, 2University of South Florida, Tampa, FL, 3University of Munich, Munich, Germany, 4Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 6Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANCA, Inflammation, nephritis and vasculitis, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis III: Pathogenic Mechanisms

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Clinical trials in rare diseases typically test therapeutic efficacy in one disease defined by a particular clinical phenotype. Improved understanding of the molecular mechanisms of disease may identify shared pathways across different clinical diseases that could be leveraged to develop stratified approaches to treatment and enable novel disease classification strategies based upon molecular rather than clinical phenotyping. An unbiased analysis of kidney diseases suggests many rare kidney diseases share common molecular profiles (Martini et al., 2014). To expand on these findings, we explored shared transcriptional responses in patients with ANCA-associated vasculitis (AAV) and nephrotic syndrome (NS) to identify common targetable disease mechanisms.

Methods: Patients with various forms of NS (minimal change disease, focal segmental glomerulosclerosis and membranous nephropathy) were recruited from the NEPTUNE cohort (n=126) and the European Renal cDNA Bank (ERCB, n=61). Patients with AAV (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) recruited from the ERCB cohort (n=80) and healthy living donors (n=37) were also studied. Patients with NS and AAV underwent standardized diagnostic kidney biopsies performed as routine clinical care. Biopsy material was micro-dissected into glomerular and tubulointerstitial compartments. Transcriptomic profiles across the two tissue compartments were generated on Affymetrix U133 and ST2.1 microarray platforms. Differential gene expression across the transcriptome was compared between patients with NS and AAV versus living donors, and shared transcriptional responses were assessed relative to living donors. Functional networks were interrogated for cross-cutting disease mechanisms, upstream regulators and potential therapeutic targets shared between both diseases.

Results: Overall, 5%-25% of expressed transcripts were differentially regulated compared to living donor in both NS and AAV in the glomerular and tubulointerstitial compartments (fold change ≥ 1.3, FDR<0.05). Findings were replicated and cross-validated across the different microarray platforms. There was significant overlap in shared directionality of change of differentially expressed genes between patients with AAV and NS in both tissue compartments (FDR<0.05). Functional analysis identified conserved, therapeutically targetable transcriptional networks in the glomeruli from patients with NS and AAV including activation of Tec kinase, IL-8 signaling, TNF, IFNG, TGFB1, and NFkappaB, while alpha catenin and retinoid-related signaling were suppressed. Transcripts causally downstream of TNF were used to develop a TNF pathway activity score across diseases, and increased TNF-related inflammatory signaling was observed in specific subsets of patients.

Conclusion:  AAV and NS, two rare kidney diseases, share common intra-renal transcriptional profiles that can be readily mined to identify shared molecular targets. Shared molecular targets can be leveraged for drug development and repurposing efforts in these rare kidney diseases.


Disclosure: S. Eddy, TheromFisher, Abbvie, Merck, Lilly, Pfizer, Gilead, 1; V. Nair, None; H. Parikh, None; M. Lindenmeyer, None; L. Mariani, None; F. H. Eichinger, None; H. Huang, None; W. Ju, None; C. Greene, None; P. C. Grayson, None; C. Cohen, None; J. Krischer, None; P. A. Merkel, Bristol Myers Squibb, 2,CaridianBCT, 2,Celgene, 2,Chemocentryx, 2,Genentech/Roche, 2,GlaxoSmithKline, 2,Kypha, 2,Bristol-Myers Squibb, 5,Chemocentryx, 5,Genentech/Roche, 5,GlaxoSmithKline, 5,PrinicipioBio, 5,Auven, 5,Proteon Therapeutics, 5; M. Kretzler, None.

To cite this abstract in AMA style:

Eddy S, Nair V, Parikh H, Lindenmeyer M, Mariani L, Eichinger FH, Huang H, Ju W, Greene C, Grayson PC, Cohen C, Krischer J, Merkel PA, Kretzler M. Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/inflammatory-pathways-as-shared-molecular-targets-across-anca-associated-vasculitis-and-nephrotic-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-pathways-as-shared-molecular-targets-across-anca-associated-vasculitis-and-nephrotic-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology